COMPANY

Mitotherapeutix, LLC

HQ: Farmington, CT source

Keywords: renal RNA therapeutics siRNA metabolic dysfunction-associated steatohepatitis fibrosis liver cirrhosis

Location: Farmington, CT · source · Oct 16, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $996K (SBIR Phase II 2R44DK129102-04A1, competing renewal, notice Sep 17, 2026). NIH RePORTER 2R44DK129102-04A1 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 2R44DK129102-04A1
  Organization: MITOTHERAPEUTIX, LLC; City/State: CHESHIRE, CT; Project number: 2R44DK129102-04A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 996169; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: cGMP Production, IND-enabling studies, and Phase I Clinical Studies to Test a Novel siRNA drug product for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH); Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals